363 related articles for article (PubMed ID: 31948475)
1. Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial.
Xiao Z; Hu L; Lin J; Lu L; Huang X; Zhu X; Teo C; Lin L
Trials; 2020 Jan; 21(1):94. PubMed ID: 31948475
[TBL] [Abstract][Full Text] [Related]
2. Shenmai injection for the treatment of cancer-related fatigue in advanced non-small cell lung cancer patients undergoing chemotherapy: study protocol for a randomized controlled trial.
Zhou Y; Zhao B; Wu W; Yang X; Long S; Deng H; He W; Liao G; Li Q; Xie Z
Trials; 2018 Sep; 19(1):474. PubMed ID: 30180874
[TBL] [Abstract][Full Text] [Related]
3. The effect of comprehensive rehabilitation program plus chemotherapy on quality of life in patients with postoperative non-small-cell lung cancer: study protocol of a multicenter randomized clinical trial.
Yao J; Jiao L; Yao Y; Lu Y; Shi J; Li J; Chen P; Xu L; Gong Y
Trials; 2020 Apr; 21(1):309. PubMed ID: 32245480
[TBL] [Abstract][Full Text] [Related]
4. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
5. Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial.
Gao R; Zhang Y; Hou W; Li J; Zhu G; Zhang X; Xu B; Wu Z; Wang H
Trials; 2021 Mar; 22(1):214. PubMed ID: 33731199
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Safety, Effectiveness, and Cost-Effectiveness of a Chinese Patent Medicine (Fufang E'jiao Syrup) for Alleviating Cancer-Related Fatigue: A Protocol for a Randomized, Double-Blinded, Placebo-Controlled, Multicenter Trial.
Song Z; Sun LY; Gu SS; Zhu XS; Lai HZ; Lu F; Cui N; Li QY; Wu Y; Xu Y
Integr Cancer Ther; 2021; 20():15347354211002919. PubMed ID: 33834863
[TBL] [Abstract][Full Text] [Related]
7. Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.
Chen W; Lin J; Yang T; Xin Zhang Z; Tao L; Xiao Z; Chen H; Qi X; Sun L; Cao Y; Lin L
Integr Cancer Ther; 2023; 22():15347354221151147. PubMed ID: 36710490
[TBL] [Abstract][Full Text] [Related]
8. Zhengyuan capsules for the treatment of chemotherapy-induced cancer-related fatigue in stage IIIB-IV unresectable NSCLC: study protocol for a randomized, multi-center, double-blind, placebo-controlled clinical trial.
Lin J; Yang T; Chen W; Qi X; Cao Y; Zheng X; Chen H; Sun L; Lin L
J Thorac Dis; 2022 Nov; 14(11):4560-4570. PubMed ID: 36524089
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer: A randomized, controlled trial.
Xiao Z; Chen Z; Han R; Lu L; Li Z; Lin J; Hu L; Huang X; Lin L
Medicine (Baltimore); 2021 May; 100(18):e25690. PubMed ID: 33950949
[TBL] [Abstract][Full Text] [Related]
10. A study protocol for HEalth-Related quality of life-intervention in survivors of Breast and other cancers experiencing cancer-related fatigue using TraditionAL Chinese Medicine: the HERBAL trial.
Yap NY; Loo WS; Zheng HF; Tan QM; Tan TK; Quek LYP; Tan CJ; Toh YL; Ng CC; Ang SK; Tan VKM; Ho HK; Chew L; Loh KW; Tan TJY; Chan A
Trials; 2020 Nov; 21(1):909. PubMed ID: 33187543
[TBL] [Abstract][Full Text] [Related]
11. Traditional Chinese Medicine Treatment as Adjuvant Therapy in Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer: Study Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Jiang Y; Liu LS; Shen LP; Liu JX; Jiang GN; Gu AQ; Li HC; Li Q; Li HG; Huang PX
Clin Lung Cancer; 2019 Sep; 20(5):e541-e547. PubMed ID: 31230892
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of Kyung-Ok-Ko on cancer-related fatigue in lung cancer patients: Study protocol for a randomized, patients-assessor blind, placebo-controlled, parallel-group, single-center trial.
Kim KI; Kong M; Lee SH; Lee BJ
Medicine (Baltimore); 2019 Nov; 98(44):e17717. PubMed ID: 31689808
[TBL] [Abstract][Full Text] [Related]
13. A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer.
Sun M; Zhou T; Fang X; Wang D; Pang H; Chen Y; Hu K
Medicine (Baltimore); 2020 Aug; 99(33):e21626. PubMed ID: 32872022
[TBL] [Abstract][Full Text] [Related]
14. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
16. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients.
Xu L; Li H; Xu Z; Wang Z; Liu L; Tian J; Sun J; Zhou L; Yao Y; Jiao L; Su W; Guo H; Chen P; Liu J
BMC Complement Altern Med; 2012 Aug; 12():112. PubMed ID: 22853619
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: study protocol for a multicenter randomized controlled trial.
Deng C; Lou Y; Gao Y; Deng B; Su F; Jia L
Trials; 2020 May; 21(1):370. PubMed ID: 32357899
[TBL] [Abstract][Full Text] [Related]
18. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
[TBL] [Abstract][Full Text] [Related]
19. Preliminary Efficacy and Safety of Reishi & Privet Formula on Quality of Life Among Non-Small Cell Lung Cancer Patients Undergoing Chemotherapy: A Randomized Placebo-Controlled Trial.
Liu J; Mao JJ; Li SQ; Lin H
Integr Cancer Ther; 2020; 19():1534735420944491. PubMed ID: 32840126
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
